PCS RECAP ON-LINE RxDRUG CLAIMS PROCESSING SYSTEM

PCS RECAP ON-LINE RxDRUG CLAIMS PROCESSING SYSTEM is in 12% of member pharmacies, the McKesson spinoff noted in its just-released annual report for fiscal 1988 (ended March 31). Recap is now linked to 7,500 of the 61,000 PCS member pharmacies and "is processing over 1 mil. claims a month," the annual report states. "We expect the system to be fully operational by late calendar-year 1989." The company explained that the Recap system allows the pharmacist to first verify a cardholder's eligibility and then to submit the claim electronically to PCS. Electronic claim submission eliminates paperwork at the pharmacy level as well as the necessity to process the claim manually. PCS estimates that it spent $ 2.5 mil. on the Recap system is fiscal 1988, and will have spent a total of $ 20 mil. on the Recap system by the time it is fully operational. "Even more significant for future growth, Recap allows us to offer clients a wide range of custom-tailored plans -- including such features as annual deductibles and maximums -- and will be able to check for drug interactions," the annual report continues. "PCS is strategically positioned to capture a growing share of the estimated 145 mil. Americans covered by employer-sponsored major medical insurance plans." With its market leadership and the expanded capabilities of the Recap system, PCS is well positioned for the prescription claim processing opportunities that are going to become available with the outpatient drug coverage provisions of the Medicare Catastrophic care bill. PCS estimates that it currently has a 12% market, compared to 7% for its nearest competitor. Cardholders increased 27% in fiscal 1988 to 7.7, while the number of claims paid rose 31% to 75.8 mil. The total $ 1.2 bil. value of claims paid during the 12 months reflects a 43% increase over fiscal 1987. Total PCS revenues were $ 76.7 mil. in fiscal 1988, an increase of 41%, while net income jumped 51% to $ 11.5 mil. Approximately 23% of revenues, or $ 17.8 mil., and about 8% of the operating profits, or just over $ 2 mil., were derived from Pharmaceutical Data Services (PDS). The annual report notes that during the year PDS' prescription audit arm, Alpha Data Service, doubled the number of retain pharmacies from which it receives data, from 5,000 to 10,000. "By 1990 that number is expected to increase to 17,000 chain and independent pharmacies from which PDS expects to capture 2 mil. prescriptions each day -- half of all prescriptions dispensed in the U.S.," the annual report states. In addition to its core Alpha Data operation, PDS offers three other services: Scriptrac, which profiles physician prescribing patterns; Consumer Data Bureau, which measures consumer attitudes about pharmaceuticals; and the tracking of hospital pharmaceuticals through affiliate International Health Services.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

To Compete With China, US FDA Must Deregulate Early Gene Therapy Studies, CAR-T Inventor Says

 

FDA regulation was painted as an obstacle to US dominance in the cell and gene therapy space even as panelists at an agency event praised the Office of Therapeutic Products' track record under Nicole Verdun.

Cell/Gene Therapy Cost Recovery Options Could Include Pre-Approval Public ‘Bridge’ Funding

 
• By 

Expanded funding for cost recovery could dovetail with FDA Commissioner Martin Makary’s idea for a “conditional approval” pathway based on a plausible mechanism of action.

House Gives US FDA More Non-User Fee Funds Than Requested

 

A US House bill would give the FDA $33.1m more in budget authority than requested by the Trump Administration for fiscal year 2026. The measure was sent to the full House Appropriations committee on a party-line vote.